{"title":"[Clinical features of acyclovir encephalopathy without acute kidney injury].","authors":"Daisuke Kuzume, Yuko Morimoto, Satoshi Tsutsumi, Masahiro Yamasaki, Naohisa Hosomi","doi":"10.3143/geriatrics.61.61","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Few reports have described acyclovir (ACV) encephalopathy without acute kidney injury (AKI).</p><p><strong>Objective: </strong>This study clarified the clinical features of ACV encephalopathy without AKI compared to that with AKI.</p><p><strong>Methods: </strong>Creatinine (Cre) levels were measured on admission. After admission, Cre was measured in a timely manner for the first seven hospital days. The minimum Cre level in these measurements was then determined. ACV encephalopathy was defined when two criteria were met: 1) neurological symptoms appeared after valacyclovir (VACV) administration, and 2) neurological symptoms improved after VACV discontinuation. AKI was defined when the Cre level on admission was >1.5 times higher than the minimum Cre level. The subjects were divided into AKI and non-AKI groups based on these findings.</p><p><strong>Results: </strong>Eighteen patients had ACV encephalopathy (5 males, mean age 81.3±5.5 years old). All patients were prescribed VACV 3,000 mg/day. The minimum Cre was 1.93±1.76 mg/dL. AKI occurred in 10 (56.6%) patients. VACV was discontinued in all patients, and emergency hemodialysis treatment was administered in 10 (55.6%) patients. All patients recovered. Compared to the AKI group, the non-AKI group had a lower history of taking a Ca-blocker (33.3% vs 80.0%, p=0.092), a lower rate of emergency dialysis (16.9% vs 70.0%, p=0.059) and a longer time to clinical improvement (3.67±1.86 vs 2.20±0.63 days, p=0.073).</p><p><strong>Conclusion: </strong>ACV encephalopathy without AKI is characterized by a low rate of emergency dialysis, which may be linked to a prolonged duration of symptoms.</p>","PeriodicalId":35593,"journal":{"name":"Japanese Journal of Geriatrics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese Journal of Geriatrics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3143/geriatrics.61.61","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Few reports have described acyclovir (ACV) encephalopathy without acute kidney injury (AKI).
Objective: This study clarified the clinical features of ACV encephalopathy without AKI compared to that with AKI.
Methods: Creatinine (Cre) levels were measured on admission. After admission, Cre was measured in a timely manner for the first seven hospital days. The minimum Cre level in these measurements was then determined. ACV encephalopathy was defined when two criteria were met: 1) neurological symptoms appeared after valacyclovir (VACV) administration, and 2) neurological symptoms improved after VACV discontinuation. AKI was defined when the Cre level on admission was >1.5 times higher than the minimum Cre level. The subjects were divided into AKI and non-AKI groups based on these findings.
Results: Eighteen patients had ACV encephalopathy (5 males, mean age 81.3±5.5 years old). All patients were prescribed VACV 3,000 mg/day. The minimum Cre was 1.93±1.76 mg/dL. AKI occurred in 10 (56.6%) patients. VACV was discontinued in all patients, and emergency hemodialysis treatment was administered in 10 (55.6%) patients. All patients recovered. Compared to the AKI group, the non-AKI group had a lower history of taking a Ca-blocker (33.3% vs 80.0%, p=0.092), a lower rate of emergency dialysis (16.9% vs 70.0%, p=0.059) and a longer time to clinical improvement (3.67±1.86 vs 2.20±0.63 days, p=0.073).
Conclusion: ACV encephalopathy without AKI is characterized by a low rate of emergency dialysis, which may be linked to a prolonged duration of symptoms.
简介:阿昔洛韦(ACV)脑病很少有报告描述阿昔洛韦(ACV)脑病不伴有急性肾损伤(AKI):本研究阐明了无急性肾损伤的阿昔洛韦脑病与有急性肾损伤的阿昔洛韦脑病的临床特征:入院时测量肌酐(Cre)水平。入院后,在头七天住院期间及时测量肌酐。然后确定这些测量结果中的最低肌酸酐水平。当符合以下两个标准时,ACV 脑病即被定义为 ACV 脑病:1)服用伐昔洛韦(VACV)后出现神经症状;2)停用 VACV 后神经症状有所改善。入院时Cre水平比最低Cre水平高出1.5倍以上即为AKI。根据这些结果将受试者分为 AKI 组和非 AKI 组:18名患者患有ACV脑病(5名男性,平均年龄(81.3±5.5)岁)。所有患者的处方均为 VACV 3,000 mg/天。最低 Cre 值为 1.93±1.76 mg/dL。10名患者(56.6%)发生了 AKI。所有患者均停用了 VACV,10 名患者(55.6%)接受了紧急血液透析治疗。所有患者均已康复。与AKI组相比,非AKI组服用Ca-受体阻滞剂的病史较少(33.3% vs 80.0%,P=0.092),紧急透析率较低(16.9% vs 70.0%,P=0.059),临床改善时间较长(3.67±1.86 vs 2.20±0.63天,P=0.073):无 AKI ACV 脑病的特点是紧急透析率低,这可能与症状持续时间长有关。